Thyroglobulin quantitation by mass spectrometry

• US 8,574,915 B2
• Filed: 04/09/2013
• Issued: 11/05/2013
• Est. Priority Date: 12/06/2007
• Status: Active Grant

• Current Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Original Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Inventors: Zhang, Yanni, Clarke, Nigel J., Reitz, Richard E.
• Primary Examiner(s): Menon, Krishnan S
• Assistant Examiner(s): Fritchman, Rebecca M
• Application Number:
  US13/859,551
• Publication Number:
  US 20130203099A1
• Time in Patent Office: 210 Days
• Field of Search: 43/86, 431/71, 431/73, 435/4, 435/7, 435/1
• US Class Current: 436/86
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 2800/7028 Cancer
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92
• CPC Class Codes: G01N 33/6848 Methods of protein analysis involving mass spectrometry
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: G01N 33/78 Thyroid gland hormones , e.g. T3, T4, TBH, TBG or their receptors
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.

Claims

1. A method for determining the amount of thyroglobulin in a test sample, comprising:

(a) digesting thyroglobulin from the test sample to form peptide T129;

(b) ionizing the peptide T129 to generate a multiply charged ion detectable by mass spectrometry;

wherein the ion has a mass/charge ratio (m/z) of 636.4±

0.5; and

(c) detecting the amount of one or more T129 fragment ions each having a m/z selected from the group consisting of 541.3±

0.5, 612.3±

0.5, 636.4±

0.5, 726.4±

0.5, 797.4±

0.5, 912.4±

0.5, and 1059.5±

0.5 by mass spectrometry;

wherein the amount of the ions detected is related to the amount of the thyroglobulin in the test sample.

2. The method of claim 1, wherein the mass spectrometry is tandem mass spectrometry.

3. The method of claim 1, wherein the detected T129 fragment ions each has a m/z selected from the group consisting of 797.4±

0.5, 912.4±

0.5, and 1059.5±

0.5.

4. The method of claim 1, further comprising purifying the peptide T129 prior to ionizing the peptide T129.

5. The method of claim 4, wherein the purification is carried out with at least one size separation technique.

6. The method of claim 1, further comprising determining the baseline amount of endogenous peptide T129 in the test sample, wherein the baseline is subtracted from the amount of peptide T129 detected in the test sample before determining the amount of thyroglobulin in the test sample.

7. The method of claim 1, wherein the ionizing of step (b) comprises ionizing the peptide T129 to generate a multiply charged peptide T129 precursor ion detectable by mass spectrometry, and colliding the peptide T129 precursor ion with a collision gas to generate one or more peptide T129 fragment ions.

8. The method of claim 1, further comprising purifying thyroglobulin from a body fluid or tissue sample to generate a thyroglobulin containing test sample.

9. The method of claim 8, wherein the body fluid or tissue sample comprises plasma or serum.

10. The method of claim 1, wherein the test sample comprises a body fluid.

11. The method of claim 10, wherein the test sample comprises plasma or serum.

12. A method for determining persistence of thyroid tissue in a patient after surgical removal of the thyroid gland, the method comprising:

(a) digesting thyroglobulin in a body fluid or tissue sample obtained from the patient to form peptide T129;

(b) ionizing the peptide T129 to generate a multiply charged ion detectable by mass spectrometry;

wherein the ion has a mass/charge ratio (m/z) of 636.4±

0.5;

(c) detecting the amount of one or more T129 fragment ions each having a m/z selected from the group consisting of 541.3±

0.5, 612.3±

0.5, 636.4±

0.5, 726.4±

0.5, 797.4±

0.5, 912.4±

0.5, and 1059.5±

0.5 by mass spectrometry, wherein the presence of the one or more T129 fragment ions indicates persistence of thyroid tissue in the patient.

13. The method of claim 12, wherein the mass spectrometry is tandem mass spectrometry.

14. The method of claim 12, wherein the detected T129 fragment ions each has a m/z selected from the group consisting of 797.4±

0.5, 912.4±

0.5, and 1059.5±

0.5.

15. The method of claim 12, further comprising purifying the peptide T129 prior to ionizing the peptide T129.

16. The method of claim 15, wherein the purification is carried out with at least one size separation technique.

17. The method of claim 12, further comprising determining the baseline amount of endogenous peptide T129 in the sample, wherein the baseline is subtracted from the amount of peptide T129 detected in the test sample before determining the presence of thyroglobulin in the sample.

18. The method of claim 12, wherein the ionizing of step (b) comprises ionizing the peptide T129 to generate a multiply charged peptide T129 precursor ion detectable by mass spectrometry, and colliding the peptide T129 precursor ion with a collision gas to generate one or more peptide T129 fragment ions.

19. The method of claim 12, further comprising purifying thyroglobulin from the body fluid or tissue sample to generate a thyroglobulin containing test sample.

20. The method of claim 12, wherein the body fluid or tissue sample comprises plasma or serum.